ZL-1310 Clinical Trials (2026): 4 Studies for SCLC & Small-cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 ZL-1310 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including SCLC & Small-cell Lung Cancer) and 1,145 total planned enrollment. 1 Phase 3 ZL-1310 trial are listed. 4 ZL-1310 clinical trials are actively recruiting at 61 U.S. sites across 21 states. Most recent activity: NCT07531095 (May 2031).
Where to Participate: All ZL-1310 Trial Sites in the U.S. (61 sites across 21 states)
Every actively recruiting ZL-1310trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | City of Hope Cancer Center Phoenix | Goodyear85338 | NCT07531095 | Map |
| CA | Zai Lab Site 02050 | La Jolla92093 | NCT07218146 | Map |
| CA | Zai Lab Site 02033 | Sacramento95817 | NCT07218146 | Map |
| CA | University of California San Francisco/Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT06885281 | Map |
| CO | Zai Lab Site 02037 | Aurora80045 | NCT07218146 | Map |
| CT | Yale Cancer Center | New Haven06519 | NCT06179069 | Map |
| CT | Zai Lab Site 02030 | New Haven06519 | NCT07218146 | Map |
| FL | Zai Lab Site 02045 | Clermont34711 | NCT07218146 | Map |
| FL | Zai Lab Site 02031 | Orange City32763 | NCT07218146 | Map |
| FL | Zai Lab Site 02020 | Rockledge32955 | NCT07218146 | Map |
| FL | Sarah Cannon Research Institute | Sarasota34232 | NCT06179069 | Map |
| FL | Zai Lab Site 02026 | Sarasota34232 | NCT07218146 | Map |
| FL | Zai Lab Site 02052 | St. Petersburg33701-4553 | NCT07218146 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07531095 | Map |
| FL | Zai Lab Site 02047 | Tampa33612 | NCT07218146 | Map |
| FL | Zai Lab Site 02051 | West Palm Beach33401 | NCT07218146 | Map |
| IL | OSF St. Francis Medical Center | Peoria61637 | NCT06885281 | Map |
| IL | Zai Lab Site 02021 | Peoria61615 | NCT07218146 | Map |
| IL | Zai Lab Site 02049 | Peoria61637 | NCT07218146 | Map |
| IL | City of Hope Chicago | Zion60099 | NCT07531095 | Map |
| IA | Zai Lab Site 02038 | Iowa City52242 | NCT07218146 | Map |
| KY | Zai Lab Site 02041 | Louisville40202 | NCT07218146 | Map |
| MD | Zai Lab Site 02003 | Bethesda20817 | NCT07218146 | Map |
| MD | Zai Lab Site 02022 | Silver Spring20904 | NCT07218146 | Map |
| MI | Barbara Ann Karmanos Cancer Institute | Detroit48201 | NCT06179069 | Map |
| MI | Karmanos Cancer Center | Detroit48201 | NCT06885281 | Map |
| MI | Zai Lab Site 02010 | Detroit48202 | NCT07218146 | Map |
| MN | Health Partners Cancer Center at Regions Hospital | Saint Paul55101 | NCT07531095 | Map |
| MO | Zai Lab Site 02023 | Columbia65201 | NCT07218146 | Map |
| MO | Zai Lab Site 02009 | St Louis63128 | NCT07218146 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06179069 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT06179069 | Map |
| NY | Memorial Sloan-Kettering Cancer Center | New York10065 | NCT06885281 | Map |
| NY | New York University Cancer Institute | New York10016 | NCT07531095 | Map |
| NY | Zai Lab Site 02040 | The Bronx10461 | NCT07218146 | Map |
| NC | Duke University | Durham27710 | NCT06179069 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06179069 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06885281 | Map |
| OH | Zai Lab Site 02024 | Cleveland44106 | NCT07218146 | Map |
| OH | Zai Lab Site 02034 | Cleveland44195 | NCT07218146 | Map |
| PA | Zai Lab Site 02035 | Broomall19008 | NCT07218146 | Map |
| PA | Zai Lab Site 02019 | Media19063 | NCT07218146 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06885281 | Map |
| PA | University of Pittsburgh Hillman Cancer Center | Pittsburgh15232 | NCT06179069 | Map |
| PA | Zai Lab Site 02008 | Pittsburgh15212 | NCT07218146 | Map |
| PA | Zai Lab Site 02029 | Pittsburgh15232 | NCT07218146 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06179069 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT07531095 | Map |
| TN | SCRI OP (Oncology Partners) | Nashville37203 | NCT06885281 | Map |
| TN | Zai Lab Site 02036 | Nashville37203 | NCT07218146 | Map |
| TX | Zai Lab Site 02025 | Austin78745 | NCT07218146 | Map |
| TX | Texas Oncology / Sammons Cancer Center | Dallas75246 | NCT06885281 | Map |
| TX | Zai Lab Site 02046 | Dallas75390-9020 | NCT07218146 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT06885281 | Map |
| TX | Texas Oncology - Central South | McAllen78503 | NCT06885281 | Map |
| TX | Zai Lab Site 02025 | Odessa79761 | NCT07218146 | Map |
| VA | Next Virginia | Fairfax22031 | NCT07531095 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT06179069 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT06885281 | Map |
| VA | Zai Lab Site 02006 | Fairfax22031 | NCT07218146 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT06885281 | Map |
ZL-1310 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 2 | 2 |
| P1/P2 | 1 | 1 |
| P3 | 1 | 1 |
Recruiting ZL-1310 clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07531095 | DeLLphi-313Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | P1 | Small Cell Lung Cancer | 160 | Apr 2026 |
| NCT07218146 | DLLEVATEA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | P3 | Small-cell Lung Cancer | 480 | Nov 2025 |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | P1/P2 | Solid Tumors | 166 | May 2025 |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | P1 | SCLC | 339 | Jan 2024 |
ZL-1310 clinical trials by indication
Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07531095 | DeLLphi-313 | P1 | recruiting | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) |
Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07218146 | DLLEVATE | P3 | recruiting | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06885281 | — | P1/P2 | recruiting | A Study of ZL-1310 in Participants With Selected Solid Tumors |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06179069 | — | P1 | recruiting | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer |
ZL-1310 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| DLLEVATE | NCT07218146 | P3 | recruiting | Small-cell Lung Cancer | 480 | — |
All ZL-1310 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07531095 | DeLLphi-313 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | P1 | recruiting | 160 | Amgen | Apr 2026 |
| NCT07218146 | DLLEVATE | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | P3 | recruiting | 480 | Zai Lab (Shanghai) Co., Ltd. | Nov 2025 |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | P1/P2 | recruiting | 166 | Zai Lab (Shanghai) Co., Ltd. | May 2025 | |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | P1 | recruiting | 339 | Zai Lab (Shanghai) Co., Ltd. | Jan 2024 |
ZL-1310 clinical trials: frequently asked questions
- How many ZL-1310 clinical trials are there?
- 4 ZL-1310 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants.
- Are ZL-1310 clinical trials recruiting in 2026?
- Yes — 4 ZL-1310 trials are actively recruiting in 2026, with 61 U.S. sites across 21 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ZL-1310 being studied for?
- ZL-1310 is being studied for SCLC, Small-cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors. The trials are grouped by indication on this page.
- What phase is ZL-1310 in?
- ZL-1310 clinical trials span 1 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ZL-1310 clinical trials?
- The lead sponsor across the most ZL-1310 trials is Zai Lab (Shanghai) Co., Ltd., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ZL-1310as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: